据报欧盟有望下周批准辉瑞新型肺炎疫苗 最快年底开始接种
《路透》报道,欧洲药品管理局(EMA)指一个专家小组将於下周一(21日)召开会议,评估辉瑞(PFE.US)与BioNTech(BNTX.US)合作研发的疫苗。而EMA是发布新药物治疗的建议,虽然欧盟执委会在批准方面拥有最终决定权,但执委会通常会遵循EMA建议。
EMA表示,在辉瑞与BioNTech按要求提供更多数据後,其专家会议将提前举行,欧盟执委会将快速推进其审批程序,可「在数天内」批准该疫苗。
德国卫生部长Jens Spahn表示,德国将在该疫苗获欧盟批准後24至72小时内开始接种,最早可能在圣诞节开始。欧盟执委会主席冯德莱恩则在Twitter上表示,很可能第一批欧洲人将在今年底之前接种疫苗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.